The pursuit of a definitive solution for treatment-resistant neurological disorders has reached a critical juncture at the University of Miami Miller School of Medicine through its leadership in the BEAT-MS clinical trial. Formally recognized as the ITN077AI study, this Phase 3 multicenter,
For nearly nine million people in the United States living with the long-term debilitating effects of a stroke, the transition from acute clinical care to daily life often represents a plateau in physical recovery that previously seemed impossible to overcome. Mobia Medical recently made a
The traditional paradigm of psychiatric care, long defined by a slow crawl toward mental stability, is currently facing a radical disruption as researchers uncover ways to compress months of healing into a single weekend. For decades, the treatment of clinical depression has remained tethered to a
The landscape of acute myeloid leukemia treatment is undergoing a radical transformation as the industry pivots from hospital-bound infusions toward the convenience of at-home oral regimens. This transition is not merely a change in delivery but a fundamental shift in how oncologists manage
The long-held biological dogma that gene-editing machinery must rely on fragile RNA strands to find its target has finally been dismantled by a pioneering shift toward DNA-guided navigation. For years, the scientific community accepted the inherent instability of RNA as a necessary trade-off for
Ivan Kairatov brings a wealth of specialized knowledge to the table, having spent years at the intersection of biopharmaceutical innovation and clinical strategy. As an expert in drug development, he has navigated the complex regulatory landscapes that define the success or failure of orphan drug
